Incidence, timing, presentation, treatment, and outcomes of second primary head and neck squamous cell carcinoma after oral cancer by ROGERS, SIMON et al.
Incidence, timing, presentation, treatment and outcomes of second primary head and 
neck squamous cell carcinoma following oral cancer  
Rogers SN, Swain A, Carroll C, Lowe D 
Professor Simon N Rogers, FDS RCS FRCS MD,  Evidence-Based Practice Research Centre 
(EPRC), Faculty of Health and Social Care,  Edge Hill University, St Helens Road, 
Ormskirk, L39 4QP and Consultant Regional Maxillofacial Unit, University Hospital 
Aintree, Liverpool, L9 1AE, UK. simonn.rogers@aintree.nhs.uk 
Aoife Swain BDS(Hons), Medical Student, Liverpool University, Cedar House, Ashton 
Street, Liverpool, L69 3GE 
aoifeswain@googlemail.com 
Conor Carrol BDS, MFDS RCSEd, Medical Student, Liverpool University, Cedar House, 
Ashton Street, Liverpool, L69 3GE 
conorcarroll9@gmail.com 
Professor Derek Lowe, MSc C.Stat Medical Statistician, Evidence-Based Practice Research 
Centre (EPRC), Faculty of Health, Edge Hill University, St Helens Road, Ormskirk, L39 
4QP. astraglobeltd@btconnect.com 
Address for correspondence: Professor Simon N Rogers, FDS RCS FRCS MD, Consultant 
Regional Maxillofacial Unit, University Hospital Aintree, Liverpool, L9 1AE, UK. 
simonn.rogers@aintree.nhs.uk 
Title page - List of all author names, their contact details and





Patients following their initial presentation of oral squamous cell carcinoma (SCC) have a 
lifelong risk of another new head and neck SCC. The present study aimed to establish the 
rates of second primary (SP), baseline characteristics (site, clinical or pathological stage, 
smoking and alcohol history), timing, presentation, treatment and outcomes. From the 
regional unit, records of patients treated with curative intent for their first oral cancer between 
2002 and 2007 inclusive were analysed. Patients had at least 10 years of follow-up either to 
death or to the end of 2017.  Of 347 patients treated with curative intent 29 had a SP at a 
median (IQR) of 52 (30-79) months after index surgery. All patients had at least 10 years of 
follow-up and the incidence of developing a second primary tumour within 2 years was 1.7% 
(95% CI: 0.7-3.7%), within 5 years was 4.9% (95% CI: 2.9-7.7% and within 10 years was 
7.8% (95% CI: 5.1-11.1%).  Early stage of first cancer was the only statistically significant 
factor (P=0.001) for SP within 10 years reflecting survivorship. SP were mainly (21 patients) 
staged as early and by visual inspection. Most (20) were located within the oral cavity with 
one of these overlapping the oropharynx, oropharynx (8) and larynx (1). The majority (22) 
were treated by surgery with curative intent and 3 were palliative. Patients need to be aware 
of the risk of SP and as most are in the mouth or oropharynx there is a role for surveillance 
by primary dental care.  
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Following treatment for oral cancer there is a risk of developing a second primary (SP). The 
rate is varies in published papers, 3% to 7% 1, 7% 2, 9% 3 11% 4,5, 13% 6 and as high as 
18.4%.7 Of the head and neck sites, oral cavity and oropharynx are more likely to develop a 
SP. 8,9,10  Risk factors include continuing smoking and alcohol consumption,11,12,13 areca quid 
chewing 5 and the presence of multiple oral dysplastic lesions.14 The location of the SP is 
influenced by causative factors for example following betel-nut chewing related oral cancer 
an annual SP incidence of 5% has been reported with three quarters occurring in the oral 
cavity. 15 The clinical significance of SP following head and neck cancer has been reflected 
in poor prognosis 10 with overall survival rates at 5 years as low as 15%. 9 Fujisawa 16 
reported that SP was the second most frequent cause of death (90 patients) in a cohort of 966 
patients with early-stage (stage I and II) oral cancer. 
 
The issue of incidence and early detection of SP is part of the debate as to the frequency and 
length of head and neck clinic follow-up following oral cancer. There is no international 
consensus. 17  It has been suggested that for oral cancer an early discharge into primary care 
after two or three years might be an appropriate use of health resources. (Kanatas) 18 
However, depending on risk of SP it could be argued that follow-up should be lifelong. 19,20 
As survival rates improve then so does the chance of developing a SP. Death is a conflicting 
variable as those who die early, and who are more likely to have advanced oral cancer, have 
less chance of developing a SP.  Although there is evidence concerning SP rates from various 
continents, the aim of this study was to estimate the yearly rates of second primary (SP) 
arising in the head and neck region for a United Kingdom based patient group. Another aim 
was to identify if any baseline characteristics (site, clinical or pathological stage, smoking 
and alcohol history) were more likely to be associated with SP rates. The final aim was to 
describe the clinical presentation, treatment and outcome of SP cases. The data might help 
inform both clinicians and patients as to a more individualised approach to follow-up based 
on perceived risk of developing SP over time. 
 
Methods 
Retrospective records of patients treated surgically and curatively for primary head and neck 
squamous cell oral carcinoma between 2002 and 2007 inclusive were reviewed. Patient 
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follow-up was to the end of 2017. Electronic case notes on SIGMA, outpatient clinical letters 
and MDT forms were used to extract data including age, site and treatment of index cancer, 
date of death, smoking and drinking status and details about the stage, site and treatment of 
the second primary tumour. For current smokers the daily consumption was known for all but 
one patient; however, the duration of smoking was unknown for almost half and when known 
was often imprecise. In the absence of clear information, a starting age of 18 was assumed, 
this being based on the US 2014 Surgeon General’s Report stating that nearly 9 out of 10 
adult smokers started before age 18 and also on a fact sheet statement from ASH that two-
thirds of smokers start before age 18. 21 On the basis of duration and amount consumed an 
estimate of pack years was obtained. For 4 patients a conversion between amount of tobacco 
(g, oz) was required in order to put it into cigarette equivalents.  
 
Diagnosis of Second Primary tumours was based on the Warren and Gates criteria 22 by 
which each lesion is distinct and separated by normal tissue, or of in a similar locality if 
greater than 3 years had elapsed.  
 
Patients had at least 10 years of follow-up either to death or to the end of 2017.  Fishers exact 
test was used to compare patient subgroups in regard to mortality and second primary tumour 
rates within 5 years and within 10 years of the primary tumour.  Estimates of cumulative 
incidence for developing second primaries beyond 10 years were derived from using the 
STATA software procedure ’stcompet’, for use with survival-time type data and with a 
competing risk (mortality).  Kaplan-Meier survival methods were used to estimate overall 
mortality rates following the diagnosis of a second primary.  Statistical significance was 
taken as p<0.05. SPSS v25 and STATA v13 were used for the analyses. 
 




347 patients were treated curatively and surgically for oral cancer at the Regional 
Maxillofacial Unit between 2002 and 2007 inclusive, comprising 61% (210) male and 39% 
(137) female. Median (IQR) age was 63 (55-73) years.  For 34% (117) the primary index 
tumour was located in the anterior two-thirds of the tongue, 29% (102) floor of mouth, 18% 
(63) buccal region, 11% (37) lower gum and 8% (28) other places. Clinical staging was early 
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(0-2) for 55% (190) and late (3-4) for 45% (157); pathological staging was early for 47% 
(162), late for 45% (157) and unknown for 8% (28). Index treatment for 63% (220) 
comprised surgery alone while 37% (127) had surgery and adjuvant radiotherapy. Nearly half 
(45%, 157) were current smokers, 22% (75) ex-smokers, 26% (91) non-smokers, with no 
documentation for 7% (24). For current smokers the estimated median (IQR) number of pack 
years was 35 (24-49).  Alcohol intake per week was either 'none/never' for 19% (67),  'low'  
(<10 units per week, social, occasional) for 24% (84), 'moderate' (10-39 units per week) for 
27% (94) or 'high' (40 or more units per week) for 20% (71), and unknown for 9% (31).   
 
Twenty-nine patients had a second primary tumour at a median (IQR) of 52 (30-79) months 
after index surgery, range 7.6-151 months. All patients had at least 10 years of follow-up and 
the incidence of developing a second primary tumour within 2 years was 1.7% (95% CI: 0.7-
3.7%), within 5 years was 4.9% (95% CI: 2.9-7.7% and within 10 years was 7.8% (95% CI: 
5.1-11.1%).  Beyond 10 years and using cumulative incidence software to analyse variable 
amounts of follow-up the cumulative incidence within 15 years was estimated as 8.8% (95% 
CI: 6.0-12.2%), Figure 1. Table 1 details the cumulative incidence over each of the first ten 
years. It also details the cumulative incidence of mortality and also information for what 
patients can expect at various survival endpoints. For example, within five years 4.9% had 
developed a second primary tumour within five years and overall 43.8% had died; some 
(unknown) of those who died might have developed a second tumour had not death 
intervened. Of those alive at five years 5.1% had had a second primary tumour. Table 2 
indicates several predictors of survival at five and ten years, notably advanced age and 
staging of the primary tumour, and (if alive) no notable association with having had a second 
primary.  Separate analyses of developing a second primary tumour within ten years yielded 
no statistically significant association other than with staging of the primary tumour, notably 
pathological staging (P=0.001) with 22 of 27 patients with second primaries having had early 
primary index tumours, reflecting survivorship following the impact of primary tumour 
staging on patient mortality.  
 
Details of presenting symptoms, staging, site and treatment of the second primary tumours 
are given in Table 3. One patient presented with both pain and swelling, 8 with a white or red 
patch, 6 with a swelling or lump, 5 with an ulcer, 4 with a sore throat or difficulty 
swallowing, 4 with pain and 1 with osteoradionecrosis. Tumours were staged mainly (21) as 
early and by visual inspection and only 2 (both late tumours) had positive neck nodes. Most 
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(20) were located within the oral cavity with one of these overlapping the oropharynx; 8 
others were in the oropharynx and one in the larynx. Fourteen patients were treated curatively 
by primary closure or laser surgery, 7 by surgery involving free-flap transfer, 4 by 
radiotherapy/chemotherapy and 1 by laryngectomy.  Three patients were referred for 
palliative care. Kaplan-Meier survival methods estimated overall survival following a SP to 




Improved long-term survival following oral cancer leads to a higher likelihood of developing 
a SP.   There are several large population-based studies reporting overall SP rates following 
HNC, 9, 23,24,25,26  however these lack detail on rates per year factoring in survivorship, also 
presentation, treatment and outcome. This study comprises a consecutive cohort and due to 
the regional service, it has been possible to carefully account for those with SP.  A very small 
number of patients with SP might have been lost to follow-up, for example those who 
subsequently move out of the regional catchment area. The length of follow up is appropriate 
with the minimum being 10 years and the date of death has allowed for precision in terms of 
statistical methodology. In the future, with younger patients and increasing elderly 
population, it would be helpful to report actual SP rates beyond 20 years. The SP rates might 
be slightly underestimated because for some patients it can be difficult to discriminate 
between recurrence or SP, and recurrence tends to be allocated if the tumour occurs in a 
similar area of the mouth within 3 years. In this study the focus has been on head and neck 
SP and other new cancer primaries such as lung or oesophageal were not considered. 9,27 Due 
to the historical case note review there was unfortunately an  inadequate record of subsequent 
alcohol intake or smoking history at clinic reviews. This would potentially have been helpful 
as these habits would be expected to increase the risk of SP. 
 
Although this data reflects the experience of only one regional unit in the UK, and caution 
needs to be applied when extrapolating the finding to other institutions, the two key finding 
are the survivorship effect and the presentation of SP. Overall, the ten-year SP rate was 8% 
with the incidence increasing year on year, at nearly 2% after two years and nearly 5% after 
five years. The overall rate is in keeping with other publications Patients with more advanced 
disease at presentation had less time to develop a SP as they tended to demise sooner than 
those with earlier oral cancer.  In addition, survival is affected by age, so the elderly who 
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demise have less time to develop a SP. 26 In our cohort most SP occurred in the mouth or 
oropharynx. Preventive strategies aimed at reducing SP occurrence such as life style advice 
related to alcohol and smoking are important elements. The symptoms of SP are those that 
could possibly be recognised in primary care thus minimising delay to referral, for example 
pain, swelling or lump, a white or red patch, ulcer, sore throat or difficulty swallowing. It is 
appropriate to inform patients of the rate, presenting symptoms and likely site of SP 
following oral cancer, so that they might reduce patient delay prior to seeking professional 
advice. They should be encouraged to keep regular surveillance with a dentist even if 
edentulous, for example every 6 months.  If they were to experience symptoms they should 
be encouraged not to wait until their scheduled appointment but get checked out early. Some 
patients might be reluctant to seek urgent opinion as they might feel that they are worrying 
needlessly and would feel embarrassed about this. Also, they might feel that they are wasting 
a clinic that a consultant could use for another patient. 
 
Early detection of a SP is a key factor in reducing further treatment burden, dysfunction and 
optimising disease specific survival. 6  Patients should be reassured by the evidence that if a 
SP is detected early most are treatable with primary closure, laser, or resection and free tissue 
reconstruction. With increasing time intervals between follow-up appointments at hospital or 
and ultimately discharge, 18 patients should have an easy mechanism to allow rapid 
assessment back into clinic if new symptoms of concern are raised. Appropriate patient 
information material needs to be developed as part of a discharge information sheet and close 
collaboration between primary and secondary care fostered. 
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If alive at 
endpoint how 
many had had a 
second primary 
 % n % n % n % n % n % n % n 
1 year 0.6 2 - - 14.7 51 84.7 294 14.7 51 0.6 2 0.7 2/296 
2 years 1.2 4 0.6 2 25.1 87 73.2 254 25.6 89 1.7 6 1.6 4/258 
3 years 1.4 5 0.9 3 31.7 110 66.0 229 32.6 113 2.3 8 2.1 5/234 
4 years 2.9 10 1.2 4 36.6 127 59.4 206 37.8 131 4.0 14 4.6 10/216 
5 years 2.9 10 2.0 7 41.8 145 53.3 185 43.8 152 4.9 17 5.1 10/195 
6 years 2.9 10 2.3 8 45.5 158 49.3 171 47.8 166 5.2 18 5.5 10/181 
7 years 3.7 13 2.9 10 48.7 169 44.5 155 51.6 179 6.6 23 7.7 13/168 
8 years 3.7 13 3.2 11 50.4 175 42.7 148 53.6 186 6.9 24 8.1 13/161 
9 years 4.3 15 3.5 12 51.6 179 40.6 141 55.0 191 7.8 27 9.6 15/156 












within 5 years 
Of those alive at 5 years 
how many had had 
a second primary 
Mortality 
within 10 years 
Of those alive at 10 years 
how many had had 
 a second primary 























 Female 40 55/137 3.7 3/82 59 81/137 7.1 4/56 








  55-64 43 51/118 4.5 3/67 55 65/118 1.9 1/53 
  65-74 39 29/75 6.5 3/46 56 42/75 12.1 4/33 
  75+ 66 46/70 0.0 0/24 86 60/70 10.0 1/10 








  Lower gum 49 18/37 0.0 0/19 57 21/37 0.0 0/16 
  Tongue (ant 2/3) 32 37/117 3.8 3/80 41 48/117 8.7 6/69 
  FOM  49 50/102 3.8 2/52 67 68/102 2.9 1/34 
 Other 64 18/28 0.0 0/10 86 24/28 0.0 0/4 








Late 3,4 56 88/157 1.4 1/69 72 113/157 0.0 0/44 








Stage) Late 3,4 58 91/157 3.0 2/66 69 109/157 4.2 2/48 
Primary 
Treatment 








Surgery+ RT 57 72/127 5.5 3/55 70 89/127 5.3 2/38 








Current (<35 pack years) 36 28/78 4.0 2/50 59 46/78 0.0 0/32 
 Ex 37 28/75 6.4 3/47 49 37/75 7.9 3/38 
 Never 41 37/91 3.7 2/54 56 51/91 15.0 6/40 
Alcohol Never/None 43 29/67  2.6 1/38  63 42/67  4.0 1/25  







0.75   10-39 units / wk 38 36/94 6.9 4/58 55 52/94 11.9 5/42 




Table 3. Details of the 29 patients who were diagnosed with second primary tumours 
 
Age at primary 
diagnosis 
Months from 






Tumour location Treatment 
Months after second 
primary to death or to 
survival at 31-12-2017 
66 7.56 Leukoplakia  T1N0 R lateral tongue Surgery (Primary closure/laser) 116  (alive) 
45 8.34 Soreness L throat T2N0 L Tonsil Surgery (Free-flap) 8  (died) 
80 12.39 Swelling  T1N0 R lip (oral) Surgery (Laser) 11  (died) 
72 14.06 Leukoplakia T1N0 Contralateral oropharynx Surgery (Primary closure/laser) 18  (died) 
52 14.26 Pain / swelling / R earache T4N0 R Oropharynx Chemo-radiotherapy 32  (died) 
70 17.91 Leukoplakia  T1N0 L buccal mucosa Surgery (Primary closure/laser) 122  (alive) 
38 24.44 Osteoradionecrosis T2N0 L mandible Surgery (Free-flap) 125  (alive) 
55 35.68 Sore throat, difficulty swallowing T3N0 R piriform Surgery (Laryngectomy) 14  (died) 
53 37.16 Increasing swelling over R cheek T4N0 R mandible Surgery (Free-flap) 87  (alive) 
71 41.46 Ulcer  T1N0 L buccal mucosa Surgery (Primary closure/laser) 94  (alive) 
45 43.07 R buccal swelling and R neck tenderness T4N2b Oropharynx Surgery (Free-flap) 7  (died) 
64 43.93 Difficulty swallowing T2N0 L oropharynx Surgery (Free-flap) 14  (died) 
55 44.48 Leukoplakia  T2N0 R anterior floor of mouth Surgery (Primary closure/laser) 82  (alive) 
58 45.83 Swelling in cheek/back of throat T2N0 R lateral tongue/oropharynx Surgery (Free-flap) 48  (died) 
53 51.68 Bleeding soft palate T2N0 Soft palate Palliative, nursing home, cognitive impairment 9  (died) 
63 51.94 Punched out ulcer R soft palate T1N0 R soft palate Surgery (Primary closure/laser) 89  (alive) 
63 57.76 Rough patch T1N0 R anterior floor of mouth   Surgery (Primary closure/laser) 51  (died) 
80 69.88 Leukoplakia T1N0 R maxillary alveolus   Surgery (Primary closure/laser) 107  (died) 
84 72.05 Leukoplakia T1N0 Anterior maxillary alveolus Palliative, cardio-respiratory comorbidity 12  (died) 
70 73.20 Difficulty swallowing T1N0 Border of tongue Surgery (Primary closure/laser) 4  (died) 
50 74.05 Lump L neck T3N1 L tonsil Chemo-radiotherapy 99  (alive) 
59 74.94 Mass R posterior tongue T2N0 R tongue  Surgery (Primary closure/laser) 34  (died) 
73 83.84 Sore patch/speckled leukoplakia  T1N0 L buccal mucosa  Surgery (Primary closure/laser) 53  (died) 
84 91.47 Necrotic ulcer  T4N0 L mandible alveolus  Palliative radiotherapy 10  (died) 
66 101.59 Sore tongue T3N0 Tongue tip Radiotherapy 12  (died) 
41 103.66 Sore tongue T1N0 R tongue Surgery (Primary closure/laser) 77  (alive) 
72 107.10 Pain  T2N0 R tongue Radiotherapy 10  (died) 
50 133.49 Pain T2N0 R tongue Surgery (Primary closure/laser) 12  (alive) 
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